Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) CEO Pascal Touchon sold 81,506 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $0.62, for a total transaction of $50,533.72. Following the completion of the sale, the chief executive officer now owns 1,829,146 shares […]
First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration
If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD
Acceptance of BLA Will Trigger $20.
ATARA Biotherapeutics (ATRA) Submits Tabelecleucel BLA for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Consensus Rating of "Hold" from Analysts wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.